Washington Trust Advisors, Inc. Kura Oncology, Inc. Transaction History
Washington Trust Advisors, Inc.
- $1.06 Billion
- Q2 2024
A detailed history of Washington Trust Advisors, Inc. transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 115 shares of KURA stock, worth $2,209. This represents 0.0% of its overall portfolio holdings.
Number of Shares
115
Previous 115
-0.0%
Holding current value
$2,209
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding KURA
# of Institutions
181Shares Held
80.2MCall Options Held
148KPut Options Held
63K-
Suvretta Capital Management, LLC New York, NY7.07MShares$136 Million6.08% of portfolio
-
Black Rock Inc. New York, NY6.97MShares$134 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.81MShares$112 Million4.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.41MShares$104 Million2.34% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.54MShares$87.2 Million3.78% of portfolio
About Kura Oncology, Inc.
- Ticker KURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,893,000
- Market Cap $1.29B
- Description
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...